These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 24349321)

  • 1. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
    Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
    PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
    Kokontis JM; Hay N; Liao S
    Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
    Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
    Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
    Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.
    Kokontis JM; Lin HP; Jiang SS; Lin CY; Fukuchi J; Hiipakka RA; Chung CJ; Chan TM; Liao S; Chang CH; Chuu CP
    PLoS One; 2014; 9(10):e109170. PubMed ID: 25271736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
    Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
    Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.
    Sen A; O'Malley K; Wang Z; Raj GV; Defranco DB; Hammes SR
    J Biol Chem; 2010 Sep; 285(37):28787-95. PubMed ID: 20628053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
    Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
    Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
    Nesslinger NJ; Shi XB; deVere White RW
    Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
    Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
    Yu P; Duan X; Cheng Y; Liu C; Chen Y; Liu W; Yin B; Wang X; Tao Z
    Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC
    J Biomed Sci; 2011 Aug; 18(1):63. PubMed ID: 21859492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
    Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
    Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
    Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
    Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
    Hakariya T; Shida Y; Sakai H; Kanetake H; Igawa T
    Biochem Biophys Res Commun; 2006 Mar; 342(1):92-100. PubMed ID: 16472761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.